United Therapeutics (UTHR) Tops Q1 EPS by 38c
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $487.61 -0.54%
EPS Growth %: -10.1%
Financial Fact:
Cost of product sales: 23.6M
Today's EPS Names:
PMCB, CULP, HURC, More
EPS Growth %: -10.1%
Financial Fact:
Cost of product sales: 23.6M
Today's EPS Names:
PMCB, CULP, HURC, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q1 EPS of $6.17, $0.38 better than the analyst estimate of $5.79. Revenue for the quarter came in at $677.7 million versus the consensus estimate of $620.31 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- FDA accepts United Therapeutics' sNDA for Tyvaso to treat IPF
- StoneX on Mama’s Creations (MAMA): 'We Remain High-Conviction Buyers'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
